Table 2.

Hazard ratios (HR) with 95% confidence intervals (CI) and log-rank p-values evaluating the tumor biomarkers cMet, Cyclin D1, p16, EGFR, and OSS DSS and RFS in both the SpSCC and non-SpSCC cohort.

		Spindle Cell		Non-Spindle Cell
Marker	Outcome	HR (95% CI)	p-value	HR (95% CI)	p-value
cMet	OSS	5.24 (2.05–13.39)	<0.001	5.80 (1.31–25.66)	0.009
	DSS	4.49 (1.39–14.57)	0.007	12.27 (2.52–59.69)	<0.001
	RFS	2.96 (1.03–8.53)	0.037	6.18 (1.38–27.54)	0.006
Cyclin D1	OSS	2.26 (0.97–5.27)	0.054	1.17 (0.51–2.67)	0.71
	DSS	3.47 (1.15–10.45)	0.019	1.42 (0.48–4.14)	0.52
	RFS	3.77 (1.25–11.37)	0.012	2.26 (0.68–7.49)	0.17
p16	OSS	1.72 (0.75–3.95)	0.20	0.88 (0.38–2.02)	0.76
	DSS	4.13 (1.46–11.68)	0.004	0.74 (0.25–2.17)	0.58
	RFS	5.49 (1.92–15.7)	<0.001	1.33 (0.56–3.17)	0.52
EGFR	OSS	2.56 (0.86–7.59)	0.079	0.53 (0.22–1.28)	0.15
	DSS	3.67 (0.81–16.57)	0.072	0.72 (0.21–2.44)	0.6
	RFS	3.33 (0.75–14.79)	0.095	1.06 (0.32–3.55)	0.92